TORONTO, ON / ACCESSWIRE / June 17, 2020 / Hypertention Diagnostics, Inc.(OTCMKTS:HDII) (“Hypertension Diagnostics” or the “Company”) CEO Liangjian Peng said he received a lot of inquiries about the Company future development. Mr. Peng thanks all inquired people, and he said the company is working on to remove the STOP sign as soon as possible, and switch to Current Pink before implementing any M&A issues.
About Hypertension Diagnostics Inc.
Hypertension Diagnostics, Inc. is a public company currently trading on the OTC Markets (HDII). HDII was originally incorporated in Minnesota.
Safe Harbor Statement Information in this press release may contain ‘forward-looking statements.’ Statements describing objectives or goals or the Company’s future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Hypertension Diagnostics Inc.’s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Hypertension Diagnostic Inc. periodic reports filed with the regulatory authorities.
CONTACT:
Jeff Peng
Liangjianpeng2018@gmail.com
SOURCE: Hypertension Diagnostics Inc.
View source version on accesswire.com:
https://www.accesswire.com/594203/Hypertention-Diagnostics-Updating-Information-to-all-Shareholders
NEW YORK CITY, NY / ACCESS Newswire / January 10, 2026 / The phrase best…
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…